New Six-Month Findings from the Vyepti® Study
At the recent Headache Cooperative of the Pacific (HCOP) Annual Conference, new six-month findings from the 12-month, real-world INFUSE study were unveiled, focusing on the effectiveness of Vyepti® (eptinezumab) in treating adults with migraines who have not responded well to other preventive treatments. These results significantly contribute to our understanding of migraine management and patient care.
Enhancements in Patient Outcomes
The data emphasizes meaningful improvements observed in patients transitioning to Vyepti®. Participants recorded reductions in the frequency of migraines and enhanced responses to treatment, representing significant progress compared to prior therapies that were not effective. This study drew upon adult patients with a history of failing at least one preventive anti-calcitonin gene-related peptide (aCGRP) treatment. With a patient-centric approach, Vyepti® appears to offer new hope for those who have long struggled with migraine intensity and frequency.
Understanding Study Outcomes
The INFUSE study included a diverse group of participants who had endured the challenges of migraine without substantial relief from previous treatments. After two infusions of eptinezumab, a staggering 75.7% of the participants noted some degree of improvement in their migraine status, as determined by the Patient Global Impression of Change Scale. Notably, 44.1% reported significant enhancements to their quality of life, demonstrating the potential of this new treatment option.
Migraine's Persistent Burden on Society
Migraine disorders affect millions worldwide, often leading to debilitating pain and a decreased quality of life. Despite a range of available treatments, many individuals experience ongoing struggles due to inadequate relief or unwanted side effects. Migraines not only dominate the personal health landscape but also impact productivity and societal dynamics. Understanding how new solutions like Vyepti® can alleviate this burden is crucial for ongoing medical research and patient support.
Significance of the INFUSE Study
The INFUSE study highlights a strategic shift towards using eptinezumab earlier in the treatment pathway for migraines. The data promote the efficacy of eptinezumab in substantially reducing the number of headache days. Moreover, participants reported an average increase of 6.3 'good days' per month, providing a refreshing perspective on improvements in daily functioning when treated with eptinezumab.
Research and Innovation in Migraine Management
Lundbeck remains dedicated to enhancing patient outcomes in migraine care through progressive clinical studies and innovative treatments. As eptinezumab gains traction, it stands as a beacon of hope for those who often feel lost in the cycle of chronic pain and ineffective treatments.
About Lundbeck
Lundbeck is a biopharmaceutical titan focusing on brain health, blending over 70 years of experience with relentless pursuit in neuroscience research. The company is committed to developing effective treatments that address some of the most challenging neurological disorders, aiming to enhance the lives of those suffering daily due to conditions like migraine. By prioritizing patient-centered care and ongoing research, Lundbeck strives to transform the landscape of migraine management.
Frequently Asked Questions
What were the main findings of the INFUSE study?
The INFUSE study revealed significant improvements in migraine frequency and overall patient-reported outcomes for those treated with Vyepti® after switching from previous aCGRP therapies.
How does Vyepti® differ from other migraine treatments?
Vyepti® is administered intravenously and has shown to be effective even in patients who failed prior migraine preventive treatments, unlike many oral or injected medications.
What is the importance of real-world studies in migraine treatment?
Real-world studies, like the INFUSE study, give insights into how treatments perform in everyday settings, providing valuable data that may not be captured in controlled trials.
Who were the participants in the INFUSE study?
The study included adults with migraines who had not responded effectively to at least one prior preventive aCGRP treatment.
How does Lundbeck contribute to brain health innovations?
Lundbeck focuses on developing transformative solutions for neurological disorders while committing resources to research and support healthcare professionals in achieving the best patient outcomes.
